Ivy Kekessie, Katarzyna Wegner, Isamir Martinez, Michael E Kopach, Timothy D White, Janine K Tom, Martin N Kenworthy, Fabrice Gallou, John Lopez, Stefan G Koenig, Philippa R Payne, Stefan Eissler, Balasubramanian Arumugam, Changfeng Li, Subha Mukherjee, Albert Isidro-Llobet, Olivier Ludemann-Hombourger, Paul Richardson, Jörg Kittelmann, Daniel Sejer Pedersen, Leendert J van den Bos
Small molecule therapeutics represent the majority of the FDA-approved drugs. Yet, many attractive targets are poorly tractable by small molecules, generating a need for new therapeutic modalities. Due to their biocompatibility profile and structural versatility, peptide-based therapeutics are a possible solution. Additionally, in the past two decades, advances in peptide design, delivery, formulation, and devices have occurred, making therapeutic peptides an attractive modality. However, peptide manufacturing is often limited to solid-phase peptide synthesis (SPPS), liquid phase peptide synthesis (LPPS), and to a lesser extent hybrid SPPS/LPPS, with SPPS emerging as a predominant platform technology for peptide synthesis...
March 20, 2024: Journal of Organic Chemistry